Devices and technology in interventional cardiologyRamachandra Barik
In the past 2 to 3 decades, the field of pediatric
interventional cardiology has experienced significant
growth. Technological innovations have greatly advanced treatment of cardiovascular disease in both children and adults with congenital heart disease (CHD). Interventional therapy has become an acceptable alternative treatment for many CHD, including closure of atrial defects,muscular ventricular septal defects (VSDs), patent ductus arteriosus (PDA), dilation of stenotic valves (aortic and pulmonary), and dilation of stenotic vessels (branch pulmonary arteries, coarctation of the aorta [COA]). In some cases where the percutaneous approach is difficult or the patient still
requires repair of other associated cardiac anomalies,
a hybrid approach can be implemented with its obvious advantages to the patient
Optimize guide catheter support
Fabrice Leroy, Lille, France
11th Experts Live CTO
The annual Euro CTO meeting
September 13th –14th, 2019 - Berlin, Germany
Devices and technology in interventional cardiologyRamachandra Barik
In the past 2 to 3 decades, the field of pediatric
interventional cardiology has experienced significant
growth. Technological innovations have greatly advanced treatment of cardiovascular disease in both children and adults with congenital heart disease (CHD). Interventional therapy has become an acceptable alternative treatment for many CHD, including closure of atrial defects,muscular ventricular septal defects (VSDs), patent ductus arteriosus (PDA), dilation of stenotic valves (aortic and pulmonary), and dilation of stenotic vessels (branch pulmonary arteries, coarctation of the aorta [COA]). In some cases where the percutaneous approach is difficult or the patient still
requires repair of other associated cardiac anomalies,
a hybrid approach can be implemented with its obvious advantages to the patient
Optimize guide catheter support
Fabrice Leroy, Lille, France
11th Experts Live CTO
The annual Euro CTO meeting
September 13th –14th, 2019 - Berlin, Germany
Despite the recent developments that have been made in the field of percutaneous left main (LM) intervention, the
treatment of distal LM bifurcation remains challenging. The provisional one-stent approach for LM bifurcation has
shown more favorable outcomes than the two-stent technique, making the former the preferred strategy in most
types of LM bifurcation stenosis. However, elective two-stent techniques, none of which has been proven superior
to the others, are still used in patients with severely diseased large side branches to avoid acute hemodynamic
compromise. Selecting the proper bifurcation treatment strategy using meticulous intravascular ultrasound evaluation
for side branch ostium is crucial for reducing the risk of side branch occlusion and for improving patient outcomes. In
addition, unnecessary complex intervention can be avoided by measuring fractional flow reserve in angiographically
isolated side branches. Most importantly, good long-term clinical outcomes are more related to the successful
procedure itself than to the type of stenting technique, emphasizing the greater importance of optimizing
the chosen technique than the choice of metho
Use of adjunct devices like cutting balloon, rotaablation, excimer laser,mechanical thrombectomy and EPD in complex PCI improve procedural success and reduce restenosis rate.
Presentation by Yaron Arbel, MD, from the Tel Aviv Medical Center, discussing the challenges facing medical device manufacturers when designing their stents
Coronary CTO is characterized by heavy atherosclerotic plaque burden within the artery, resulting in complete (or nearly complete) occlusion of the vessel. Although the duration of the occlusion is difficult to determine on clinical grounds, a total occlusion must be present for at least 3 months to be considered a true CTO. Patients with CTO typically have collateralization of the distal vessel on coronary angiography, but these collaterals may not provide sufficient blood flow to the myocardial bed, resulting in ischemia and anginal symptoms. CTO is clinically distinct from acute coronary occlusion, which occurs in the setting of ST-segment–elevation myocardial infarction, or subacute coronary occlusion, discovered with delayed presentation after ST-segment–elevation myocardial infarction. Clinical features and treatment considerations of these entities differ considerably from CTO.
Among patients who have a clinical indication for coronary angiography, the incidence of CTO has been reported to be as high as 15% to 30%. Patients with CTO are referred for angiography because of anginal symptoms or significant ischemia on noninvasive ischemia testing. Patients who are symptomatic will have stable exertional angina resulting from a limitation of collateral vessel flow to meet myocardial oxygen demand with stress. Of patients referred for PCI in clinical trials of CTO PCI, only 10% to 15% of patients are asymptomatic. It is likewise uncommon for patients with CTO to present with an acute coronary syndrome caused by the CTO itself.
Despite the recent developments that have been made in the field of percutaneous left main (LM) intervention, the
treatment of distal LM bifurcation remains challenging. The provisional one-stent approach for LM bifurcation has
shown more favorable outcomes than the two-stent technique, making the former the preferred strategy in most
types of LM bifurcation stenosis. However, elective two-stent techniques, none of which has been proven superior
to the others, are still used in patients with severely diseased large side branches to avoid acute hemodynamic
compromise. Selecting the proper bifurcation treatment strategy using meticulous intravascular ultrasound evaluation
for side branch ostium is crucial for reducing the risk of side branch occlusion and for improving patient outcomes. In
addition, unnecessary complex intervention can be avoided by measuring fractional flow reserve in angiographically
isolated side branches. Most importantly, good long-term clinical outcomes are more related to the successful
procedure itself than to the type of stenting technique, emphasizing the greater importance of optimizing
the chosen technique than the choice of metho
Use of adjunct devices like cutting balloon, rotaablation, excimer laser,mechanical thrombectomy and EPD in complex PCI improve procedural success and reduce restenosis rate.
Presentation by Yaron Arbel, MD, from the Tel Aviv Medical Center, discussing the challenges facing medical device manufacturers when designing their stents
Coronary CTO is characterized by heavy atherosclerotic plaque burden within the artery, resulting in complete (or nearly complete) occlusion of the vessel. Although the duration of the occlusion is difficult to determine on clinical grounds, a total occlusion must be present for at least 3 months to be considered a true CTO. Patients with CTO typically have collateralization of the distal vessel on coronary angiography, but these collaterals may not provide sufficient blood flow to the myocardial bed, resulting in ischemia and anginal symptoms. CTO is clinically distinct from acute coronary occlusion, which occurs in the setting of ST-segment–elevation myocardial infarction, or subacute coronary occlusion, discovered with delayed presentation after ST-segment–elevation myocardial infarction. Clinical features and treatment considerations of these entities differ considerably from CTO.
Among patients who have a clinical indication for coronary angiography, the incidence of CTO has been reported to be as high as 15% to 30%. Patients with CTO are referred for angiography because of anginal symptoms or significant ischemia on noninvasive ischemia testing. Patients who are symptomatic will have stable exertional angina resulting from a limitation of collateral vessel flow to meet myocardial oxygen demand with stress. Of patients referred for PCI in clinical trials of CTO PCI, only 10% to 15% of patients are asymptomatic. It is likewise uncommon for patients with CTO to present with an acute coronary syndrome caused by the CTO itself.
Diabetes in surgery (evidence based management protocol)Hriday Ranjan Roy
25% diabetic patient need surgery. He or she may have surgical disease along with diabetes or diabetes may complicate to surgical conditions. So it is critical to manage diabetes during surgical events.
Back to the Bedside: Internal Medicine Bedside Ultrasound ProgramAllina Health
David Tierney, MD. How bedside ultrasound is changing the practice of medicine and how Abbott Northwestern Hospital has become a national leader in integrating bedside ultrasound in its Internal Medicine Residency Program. "As internal medicine physicians, we are finding that everything we do with our hands, eyes and stethoscopes can be done a little better with ultrasound. That means our physical exam, which we consider our bread and butter, has more sensitivity and specificity. This gives us better diagnostic ability and results in earlier and more appropriate treatment."
Dr Ashling Lillis, National Director's Clinical Fellow Macmillan Support, final year trainee in Acute Oncology
Dr Clare Philliskirk, Trainee in Acute Medicine, West Midlands
Dr Sarbit Clare, Acute Medical Consultant, Sandwell and West Birmingham Hospitals
Stroke is the 2nd leading death associated disorder. It is also known as cerebrovascular disorder mainly caused by high blood cholesterol levels or rupture of cerebral arteries.
Recomendações da OMS sobre cuidados maternos e neonatais para uma experiência pós-natal positiva.
Em consonância com os ODS – Objetivos do Desenvolvimento Sustentável e a Estratégia Global para a Saúde das Mulheres, Crianças e Adolescentes, e aplicando uma abordagem baseada nos direitos humanos, os esforços de cuidados pós-natais devem expandir-se para além da cobertura e da simples sobrevivência, de modo a incluir cuidados de qualidade.
Estas diretrizes visam melhorar a qualidade dos cuidados pós-natais essenciais e de rotina prestados às mulheres e aos recém-nascidos, com o objetivo final de melhorar a saúde e o bem-estar materno e neonatal.
Uma “experiência pós-natal positiva” é um resultado importante para todas as mulheres que dão à luz e para os seus recém-nascidos, estabelecendo as bases para a melhoria da saúde e do bem-estar a curto e longo prazo. Uma experiência pós-natal positiva é definida como aquela em que as mulheres, pessoas que gestam, os recém-nascidos, os casais, os pais, os cuidadores e as famílias recebem informação consistente, garantia e apoio de profissionais de saúde motivados; e onde um sistema de saúde flexível e com recursos reconheça as necessidades das mulheres e dos bebês e respeite o seu contexto cultural.
Estas diretrizes consolidadas apresentam algumas recomendações novas e já bem fundamentadas sobre cuidados pós-natais de rotina para mulheres e neonatos que recebem cuidados no pós-parto em unidades de saúde ou na comunidade, independentemente dos recursos disponíveis.
É fornecido um conjunto abrangente de recomendações para cuidados durante o período puerperal, com ênfase nos cuidados essenciais que todas as mulheres e recém-nascidos devem receber, e com a devida atenção à qualidade dos cuidados; isto é, a entrega e a experiência do cuidado recebido. Estas diretrizes atualizam e ampliam as recomendações da OMS de 2014 sobre cuidados pós-natais da mãe e do recém-nascido e complementam as atuais diretrizes da OMS sobre a gestão de complicações pós-natais.
O estabelecimento da amamentação e o manejo das principais intercorrências é contemplada.
Recomendamos muito.
Vamos discutir essas recomendações no nosso curso de pós-graduação em Aleitamento no Instituto Ciclos.
Esta publicação só está disponível em inglês até o momento.
Prof. Marcus Renato de Carvalho
www.agostodourado.com
Prix Galien International 2024 Forum ProgramLevi Shapiro
June 20, 2024, Prix Galien International and Jerusalem Ethics Forum in ROME. Detailed agenda including panels:
- ADVANCES IN CARDIOLOGY: A NEW PARADIGM IS COMING
- WOMEN’S HEALTH: FERTILITY PRESERVATION
- WHAT’S NEW IN THE TREATMENT OF INFECTIOUS,
ONCOLOGICAL AND INFLAMMATORY SKIN DISEASES?
- ARTIFICIAL INTELLIGENCE AND ETHICS
- GENE THERAPY
- BEYOND BORDERS: GLOBAL INITIATIVES FOR DEMOCRATIZING LIFE SCIENCE TECHNOLOGIES AND PROMOTING ACCESS TO HEALTHCARE
- ETHICAL CHALLENGES IN LIFE SCIENCES
- Prix Galien International Awards Ceremony
263778731218 Abortion Clinic /Pills In Harare ,sisternakatoto
263778731218 Abortion Clinic /Pills In Harare ,ABORTION WOMEN’S CLINIC +27730423979 IN women clinic we believe that every woman should be able to make choices in her pregnancy. Our job is to provide compassionate care, safety,affordable and confidential services. That’s why we have won the trust from all generations of women all over the world. we use non surgical method(Abortion pills) to terminate…Dr.LISA +27730423979women Clinic is committed to providing the highest quality of obstetrical and gynecological care to women of all ages. Our dedicated staff aim to treat each patient and her health concerns with compassion and respect.Our dedicated group ABORTION WOMEN’S CLINIC +27730423979 IN women clinic we believe that every woman should be able to make choices in her pregnancy. Our job is to provide compassionate care, safety,affordable and confidential services. That’s why we have won the trust from all generations of women all over the world. we use non surgical method(Abortion pills) to terminate…Dr.LISA +27730423979women Clinic is committed to providing the highest quality of obstetrical and gynecological care to women of all ages. Our dedicated staff aim to treat each patient and her health concerns with compassion and respect.Our dedicated group of receptionists, nurses, and physicians have worked together as a teamof receptionists, nurses, and physicians have worked together as a team wwww.lisywomensclinic.co.za/
Lung Cancer: Artificial Intelligence, Synergetics, Complex System Analysis, S...Oleg Kshivets
RESULTS: Overall life span (LS) was 2252.1±1742.5 days and cumulative 5-year survival (5YS) reached 73.2%, 10 years – 64.8%, 20 years – 42.5%. 513 LCP lived more than 5 years (LS=3124.6±1525.6 days), 148 LCP – more than 10 years (LS=5054.4±1504.1 days).199 LCP died because of LC (LS=562.7±374.5 days). 5YS of LCP after bi/lobectomies was significantly superior in comparison with LCP after pneumonectomies (78.1% vs.63.7%, P=0.00001 by log-rank test). AT significantly improved 5YS (66.3% vs. 34.8%) (P=0.00000 by log-rank test) only for LCP with N1-2. Cox modeling displayed that 5YS of LCP significantly depended on: phase transition (PT) early-invasive LC in terms of synergetics, PT N0—N12, cell ratio factors (ratio between cancer cells- CC and blood cells subpopulations), G1-3, histology, glucose, AT, blood cell circuit, prothrombin index, heparin tolerance, recalcification time (P=0.000-0.038). Neural networks, genetic algorithm selection and bootstrap simulation revealed relationships between 5YS and PT early-invasive LC (rank=1), PT N0—N12 (rank=2), thrombocytes/CC (3), erythrocytes/CC (4), eosinophils/CC (5), healthy cells/CC (6), lymphocytes/CC (7), segmented neutrophils/CC (8), stick neutrophils/CC (9), monocytes/CC (10); leucocytes/CC (11). Correct prediction of 5YS was 100% by neural networks computing (area under ROC curve=1.0; error=0.0).
CONCLUSIONS: 5YS of LCP after radical procedures significantly depended on: 1) PT early-invasive cancer; 2) PT N0--N12; 3) cell ratio factors; 4) blood cell circuit; 5) biochemical factors; 6) hemostasis system; 7) AT; 8) LC characteristics; 9) LC cell dynamics; 10) surgery type: lobectomy/pneumonectomy; 11) anthropometric data. Optimal diagnosis and treatment strategies for LC are: 1) screening and early detection of LC; 2) availability of experienced thoracic surgeons because of complexity of radical procedures; 3) aggressive en block surgery and adequate lymph node dissection for completeness; 4) precise prediction; 5) adjuvant chemoimmunoradiotherapy for LCP with unfavorable prognosis.
Report Back from SGO 2024: What’s the Latest in Cervical Cancer?bkling
Are you curious about what’s new in cervical cancer research or unsure what the findings mean? Join Dr. Emily Ko, a gynecologic oncologist at Penn Medicine, to learn about the latest updates from the Society of Gynecologic Oncology (SGO) 2024 Annual Meeting on Women’s Cancer. Dr. Ko will discuss what the research presented at the conference means for you and answer your questions about the new developments.
ARTIFICIAL INTELLIGENCE IN HEALTHCARE.pdfAnujkumaranit
Artificial intelligence (AI) refers to the simulation of human intelligence processes by machines, especially computer systems. It encompasses tasks such as learning, reasoning, problem-solving, perception, and language understanding. AI technologies are revolutionizing various fields, from healthcare to finance, by enabling machines to perform tasks that typically require human intelligence.
Title: Sense of Smell
Presenter: Dr. Faiza, Assistant Professor of Physiology
Qualifications:
MBBS (Best Graduate, AIMC Lahore)
FCPS Physiology
ICMT, CHPE, DHPE (STMU)
MPH (GC University, Faisalabad)
MBA (Virtual University of Pakistan)
Learning Objectives:
Describe the primary categories of smells and the concept of odor blindness.
Explain the structure and location of the olfactory membrane and mucosa, including the types and roles of cells involved in olfaction.
Describe the pathway and mechanisms of olfactory signal transmission from the olfactory receptors to the brain.
Illustrate the biochemical cascade triggered by odorant binding to olfactory receptors, including the role of G-proteins and second messengers in generating an action potential.
Identify different types of olfactory disorders such as anosmia, hyposmia, hyperosmia, and dysosmia, including their potential causes.
Key Topics:
Olfactory Genes:
3% of the human genome accounts for olfactory genes.
400 genes for odorant receptors.
Olfactory Membrane:
Located in the superior part of the nasal cavity.
Medially: Folds downward along the superior septum.
Laterally: Folds over the superior turbinate and upper surface of the middle turbinate.
Total surface area: 5-10 square centimeters.
Olfactory Mucosa:
Olfactory Cells: Bipolar nerve cells derived from the CNS (100 million), with 4-25 olfactory cilia per cell.
Sustentacular Cells: Produce mucus and maintain ionic and molecular environment.
Basal Cells: Replace worn-out olfactory cells with an average lifespan of 1-2 months.
Bowman’s Gland: Secretes mucus.
Stimulation of Olfactory Cells:
Odorant dissolves in mucus and attaches to receptors on olfactory cilia.
Involves a cascade effect through G-proteins and second messengers, leading to depolarization and action potential generation in the olfactory nerve.
Quality of a Good Odorant:
Small (3-20 Carbon atoms), volatile, water-soluble, and lipid-soluble.
Facilitated by odorant-binding proteins in mucus.
Membrane Potential and Action Potential:
Resting membrane potential: -55mV.
Action potential frequency in the olfactory nerve increases with odorant strength.
Adaptation Towards the Sense of Smell:
Rapid adaptation within the first second, with further slow adaptation.
Psychological adaptation greater than receptor adaptation, involving feedback inhibition from the central nervous system.
Primary Sensations of Smell:
Camphoraceous, Musky, Floral, Pepperminty, Ethereal, Pungent, Putrid.
Odor Detection Threshold:
Examples: Hydrogen sulfide (0.0005 ppm), Methyl-mercaptan (0.002 ppm).
Some toxic substances are odorless at lethal concentrations.
Characteristics of Smell:
Odor blindness for single substances due to lack of appropriate receptor protein.
Behavioral and emotional influences of smell.
Transmission of Olfactory Signals:
From olfactory cells to glomeruli in the olfactory bulb, involving lateral inhibition.
Primitive, less old, and new olfactory systems with different path
These lecture slides, by Dr Sidra Arshad, offer a quick overview of physiological basis of a normal electrocardiogram.
Learning objectives:
1. Define an electrocardiogram (ECG) and electrocardiography
2. Describe how dipoles generated by the heart produce the waveforms of the ECG
3. Describe the components of a normal electrocardiogram of a typical bipolar leads (limb II)
4. Differentiate between intervals and segments
5. Enlist some common indications for obtaining an ECG
Study Resources:
1. Chapter 11, Guyton and Hall Textbook of Medical Physiology, 14th edition
2. Chapter 9, Human Physiology - From Cells to Systems, Lauralee Sherwood, 9th edition
3. Chapter 29, Ganong’s Review of Medical Physiology, 26th edition
4. Electrocardiogram, StatPearls - https://www.ncbi.nlm.nih.gov/books/NBK549803/
5. ECG in Medical Practice by ABM Abdullah, 4th edition
6. ECG Basics, http://www.nataliescasebook.com/tag/e-c-g-basics
HOT NEW PRODUCT! BIG SALES FAST SHIPPING NOW FROM CHINA!! EU KU DB BK substit...GL Anaacs
Contact us if you are interested:
Email / Skype : kefaya1771@gmail.com
Threema: PXHY5PDH
New BATCH Ku !!! MUCH IN DEMAND FAST SALE EVERY BATCH HAPPY GOOD EFFECT BIG BATCH !
Contact me on Threema or skype to start big business!!
Hot-sale products:
NEW HOT EUTYLONE WHITE CRYSTAL!!
5cl-adba precursor (semi finished )
5cl-adba raw materials
ADBB precursor (semi finished )
ADBB raw materials
APVP powder
5fadb/4f-adb
Jwh018 / Jwh210
Eutylone crystal
Protonitazene (hydrochloride) CAS: 119276-01-6
Flubrotizolam CAS: 57801-95-3
Metonitazene CAS: 14680-51-4
Payment terms: Western Union,MoneyGram,Bitcoin or USDT.
Deliver Time: Usually 7-15days
Shipping method: FedEx, TNT, DHL,UPS etc.Our deliveries are 100% safe, fast, reliable and discreet.
Samples will be sent for your evaluation!If you are interested in, please contact me, let's talk details.
We specializes in exporting high quality Research chemical, medical intermediate, Pharmaceutical chemicals and so on. Products are exported to USA, Canada, France, Korea, Japan,Russia, Southeast Asia and other countries.
Ozempic: Preoperative Management of Patients on GLP-1 Receptor Agonists Saeid Safari
Preoperative Management of Patients on GLP-1 Receptor Agonists like Ozempic and Semiglutide
ASA GUIDELINE
NYSORA Guideline
2 Case Reports of Gastric Ultrasound
New Directions in Targeted Therapeutic Approaches for Older Adults With Mantl...i3 Health
i3 Health is pleased to make the speaker slides from this activity available for use as a non-accredited self-study or teaching resource.
This slide deck presented by Dr. Kami Maddocks, Professor-Clinical in the Division of Hematology and
Associate Division Director for Ambulatory Operations
The Ohio State University Comprehensive Cancer Center, will provide insight into new directions in targeted therapeutic approaches for older adults with mantle cell lymphoma.
STATEMENT OF NEED
Mantle cell lymphoma (MCL) is a rare, aggressive B-cell non-Hodgkin lymphoma (NHL) accounting for 5% to 7% of all lymphomas. Its prognosis ranges from indolent disease that does not require treatment for years to very aggressive disease, which is associated with poor survival (Silkenstedt et al, 2021). Typically, MCL is diagnosed at advanced stage and in older patients who cannot tolerate intensive therapy (NCCN, 2022). Although recent advances have slightly increased remission rates, recurrence and relapse remain very common, leading to a median overall survival between 3 and 6 years (LLS, 2021). Though there are several effective options, progress is still needed towards establishing an accepted frontline approach for MCL (Castellino et al, 2022). Treatment selection and management of MCL are complicated by the heterogeneity of prognosis, advanced age and comorbidities of patients, and lack of an established standard approach for treatment, making it vital that clinicians be familiar with the latest research and advances in this area. In this activity chaired by Michael Wang, MD, Professor in the Department of Lymphoma & Myeloma at MD Anderson Cancer Center, expert faculty will discuss prognostic factors informing treatment, the promising results of recent trials in new therapeutic approaches, and the implications of treatment resistance in therapeutic selection for MCL.
Target Audience
Hematology/oncology fellows, attending faculty, and other health care professionals involved in the treatment of patients with mantle cell lymphoma (MCL).
Learning Objectives
1.) Identify clinical and biological prognostic factors that can guide treatment decision making for older adults with MCL
2.) Evaluate emerging data on targeted therapeutic approaches for treatment-naive and relapsed/refractory MCL and their applicability to older adults
3.) Assess mechanisms of resistance to targeted therapies for MCL and their implications for treatment selection
micro teaching on communication m.sc nursing.pdfAnurag Sharma
Microteaching is a unique model of practice teaching. It is a viable instrument for the. desired change in the teaching behavior or the behavior potential which, in specified types of real. classroom situations, tends to facilitate the achievement of specified types of objectives.
Pulmonary Thromboembolism - etilogy, types, medical- Surgical and nursing man...VarunMahajani
Disruption of blood supply to lung alveoli due to blockage of one or more pulmonary blood vessels is called as Pulmonary thromboembolism. In this presentation we will discuss its causes, types and its management in depth.
Pulmonary Thromboembolism - etilogy, types, medical- Surgical and nursing man...
a case of Bifurcation Stenting- Dr Zarrar
1.
2. CASE OF THE WEEK
BY
DR. M. ZARRAR ARIF
PGR CARDIOLOGY
3. HISTORY
PATIENT DATA
Name: Babar Abbas
Age / Gender : 45 y / Male
MOA : Medical Emergency
DOA : 11-03-2011
Address: 149 F Model Town, Lahore
4. HISTORY
PRESENTING COMPLAINTS
Chest pain for last 2 hours
HOPI
Patient was in usual state of health when
he developed complaints of sudden chest
pain, central in location, radiating to left
arm and neck, severe in intensity and was
associated with sweating. No complaints
of nausea, vomiting, palpitations or
dyspnoea.
5. HISTORY
Past History
Patient gives history of admission with
chest pain 2 days back for which he was
admitted in Ittefaq hospital and he was
advised stay for evaluation after an ECG
but he was discharged on his request.
No previous history of any other hospital
stay, surgical interventions etc
6. HISTORY
Drug History
Patient has been taking following
medications since last 2 days
Asprin 75 mg OD
Clopidogrel 75 mg OD
Atorvastatin 20 mg HS
Metoprolol 25 mg BD
Lisinopril 5 mg HS
No history of drug allergy.
7. HISTORY
Personal History
Patient has no history of smoking or any
other addiction
Occupational History
Patient is a school teacher by profession
Family History
No history of DM, IHD in the family
8. GPE
A middle aged man sitting in bed well
oriented in time place and person with
vitals
Pulse : 72 / min, regular, normal character
with no radio-radial and no radio-femoral
delay.
B.P : 160/100 mm Hg
Temp : 980 F
R/R : 16 / min
-ve for Pallor, clubbing, cyanosis.
JVP not raised.
9. SYSTEMIC EXAMINATION
Cardio Vascular System
On pre-cordial examination inspection
normal, on palpation apex beat in 4th
intercostal space with normal character, on
auscultation first and second heart sounds
normal with no added sound.
Respiratory System
Normal findings on inspection palpation
and percussion with normal vesicular
breathing bilaterally and no added sounds
on auscultation.
10. SYSTEMIC EXAMINATION
Gastro Intestinal System
Normal findings on inspection with no
palpable visceromegally and no area of
tenderness on palpation, normal bowel
sounds on auscultation.
Central Nervous System
Grossly intact HMF with no motor or
sensory loss
13. ECG
ECG findings are as below
It showed regular sinus rhythm with rate of
80/min, normal axis with normal PR, and
QT intervals with normal QRS.
STT changes were present in anterior
chest leads from V1-V4 in form of ST
segment depression and T wave
inversions, no ST elevations seen in any
leads.
15. TREATMENT
Emergency management was done with
S/L angisid 0.5 mg stat
Asprin 300 mg stat
Clopidogrel 300 mg stat
Morphine 3mg stat
Metoprolol 25 mg stat
Infusion of isoket @ 10 u drops/min
Clexane 80 mg S/C Stat
Chest pain improved with medication and
ECG also showed improvement
17. CORONARY ANGIOGRAM
• Patient was offered coronary angiogram
as it was Class I A indication according to
AHA guidelines
• Recommendations for Coronary
Angiography in Unstable Coronary
Syndromes
Class I
High- or intermediate-risk unstable
angina that stabilizes after initial
treatment. (Level of Evidence: A)
19. DECISION
Patient was advised PTCA for his disease
and for the complete decision we will have
to review the type of lesion we r facing
20. How to define a bifurcation
lesion ?
• “A coronary artery narrowing occurring
adjacent to, and/or involving, the origin
of a significant side branch"
• A significant SB is a branch that you
don't want to loose in the global
context of a particular patient
21. Difficulties of Bifurcation PCI
• Risk of peri-procedural complications
• Relatively high re-stenosis
• Not all lesions are the same :
- Size of vessels (Meaningful SB size ≥2.25mm)
- Variable plaque distribution
- Extent of SB disease
- Variable angulations
• Higher risk of stent thrombosis
• PCI techniques are mainly based on
personal experiences from skilled
operators
22. Factors to be considered for
PCI strategy
• Anatomical factors
– LMCA bifurcation
– Location of plaque (Anatomical classification)
– Plaque or carina shift
– Angle between SB and MB
– Dynamic change in bifurcation anatomy
• Modalities for objective anatomical
evaluation
– QCA, IVUS, FFR
• Selection of devices and strategies
– DES vs. BMS
– Single vs. Double stent techniques
– Kissing balloon or not
– Dedicated bifurcation stents
26. Limitations of
the Medina classification
• Does not take into account
1. Length of disease in the ostium of
the SB
2. Length of the LMCA before the
bifurcation
3. Trifurcation
4. Vessel angulation
• The LMCA differs from many
other bifurcation lesions due to
the importance of the SB (LCx)
45. CONCLUSION
In cases where there is no lesion in the
side branch or a purely ostial lesion,
stenting the main branch with a jailed wire
in the side branch followed by provisional
T-Stenting of the side branch after guide
wire exchange appears to be the most
rational and successful strategy, provided
that final kissing-balloon inflations are
systematically performed.